FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **GLOBAL HEMP GROUP INC.** (the "Issuer").

Trading Symbol: **GHG**

Number of Outstanding Listed Securities: **355,693,392**

Date: **March 5, 2023**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

GREEN COMMUNITY IN HAYDEN COLORADO

As previously announced, the Company has experienced significant delays in its payment obligations under the original Definitive Agreement executed with Western Sierra Resources Corporation (WSRC) and Prescient Solutions Group LLC relating to the Green Community/HAIZ Project in Hayden Colorado. During the course of 2022 the Company has worked with WSRC to restructure the Definitive Agreement to clarify and simplify the relationship of the parties, with the execution of either a revised Definitive Agreement or Joint Venture agreement. Over the last 10 days January GHG and its capital markets Advisor had discussions with WSRC regarding potential direct funding partners for the project under a new Joint Venture scenario. These negotiations did not reach a successful conclusion; therefore, the Definitive Agreement between the Parties has been terminated.

RESEARCH & DEVELOPMENT DIVISION - EXPANSION OF ACTIVITIES

The R&D Division in Querétaro Mexico continues to be an important component of Company's business model. The R&D team is currently focused on development of patented technology ("IP") that can be widely marketed, as well as expanding working opportunities in a number of regions in the country.

The group is completing work on two initial patents that it expects to file early in 2023. The first, a novel building material utilizing hemp fibre that has been chemically modified to increase its mechanical performance and then combined with rice husks, an important agricultural by-product found worldwide, creating a product that could be used as a replacement for Medium-Density Fibreboard (MDF) in construction. As rice husks are not biodegradable, this is an ideal method for utilizing the waste from the rice industry. The second patent is an environmentally friendly procedure to extract CDB and other cannabinoids from hemp utilizing enzymes from natural products. The process has proven to be economical, while leaving no residual chemicals or solvents.

The R&D group is also actively exploring additional academic and economic partnerships to expand its research endeavours relating to hemp and hemp-based products.

CHANGES TO THE COMPANY'S BOARD OF DIRECTORS

In the month of February there were a number of changes to the Company's Board of Directors. Please see #16 below for further details.

APPOINTMENT OF ADVISORS

On February 17, 2023 the Company announced the addition of Mathieu Couillard and the continuing engagement of Twilight Capital on its Advisory Board.

The Company welcomed Mathieu Couillard as its Business Development and Capital Markets Advisor. Mr. Couillard served as Managing Director of investment banking at Haywood Securities, leading the Special Situations team from 2016 to 2022. Mr. Couillard is an experienced investment banker who has extensive experience in the cannabis space. He has participated in over $1 Billion in capital raises for cannabis companies from start-ups to some of the largest players in the industry. He is the architect of numerous mergers and acquisitions.

Prior to joining Haywood Securities Mr. Couillard was part of the Risk Management Solutions group specializing in the sales and structuring of derivative products at National Bank of Canada in Toronto. From 2006 to 2014, Mr. Couillard was part of National Bank's investment banking group in Montreal. Mr. Couillard is a Fellow of the Society of Actuaries.

The Company also announced the continuing engagement of Twilight Capital as Special Advisor/Capital Markets. Twilight Capital is an M&A and Capital Markets Advisory consulting firm headed by Nikolas Perrault. Mr. Perrault is a Chartered Financial Analyst with significant experience in the technology, financial, and natural resources industries. He provides strategic advice to select clients on a global scale.

Mr. Perrault obtained his Chartered Financial Analyst designation in 1997, and spent the first 15 years of his career with Canada's large institutions like National Bank, Merrill Lynch, CIBC, and Scotia Capital. His focus throughout his career has been on small to medium-cap companies worldwide which allowed him to develop an extensive international network.

Subscribe to our YouTube channel

Follow us on LinkedIn

Follow us on Instagram @hemp_global

Like us on Facebook @globalhempgrp

Follow us on Twitter @Hemp_Global

2. Provide a general overview and discussion of the activities of management.
See #1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
See #1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On February 6, 2023, the Company announced that it has executed a consulting contract with Dr. Stephen D. Barnhill, MD to join the GHG team as Special Medical Advisor. Dr. Barnhill is Chairman & CEO of Apollon Formularies, Plc and a Medical Doctor specializing in Cannabinoid and Mycomedicinal Therapeutics, Drug Discovery and Artificial Intelligence, and has completed a Clinical Fellowship in Laboratory Medicine (Clinical Pathology) at the Medical University of South Carolina (MUSC).

Previously, Dr. Barnhill was Founder, Chairman and CEO of both private and public companies, including Founder, Chairman, and CEO of BCL laboratories, LLC with operations in southeastern US, which was acquired by Corning–MetPath now Quest Diagnostics, the largest clinical laboratory in the world.

Per the binding LOI executed by the Company with Apollon on January 9, 2023, Dr. Barnhill was issued 10 million common shares of GHG for his services as Special Medical Advisor. The shares have a hold period of four months and one day, calculated from the date of issuance.

Dr. Barnhill will advise the Company on natural biologic therapeutics, as well as assist the GHG as it looks to begin an IP sub-licensing program of its recently acquired exclusive North American licensing of Apollon Formularies plc patents and

IP to legally licensed manufacturers, distributors, and retailers in any and all locations where legally permitted in the United States, Canada, and Mexico.

Apollon is a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
None

8. Describe the acquisition of new customers or loss of customers.
None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **None**

11. Report on any labour disputes and resolutions of those disputes if applicable.
None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **None**

14. Provide details of any securities issued/returned to treasury, and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds (1)
Incentive Stock Options	**17,900,000**	Feb 17/23 - The Company granted incentive stock options to Directors, Officers and Consultants to acquire up to an aggregate of 17,900,000 common shares in the capital stock of the Company. The options vest immediately, are exercisable at a price of $0.05 per share for a period of five years from the date of the grant.	**N/A**
Incentive Stock Options	**17,900,000**	Feb 22/23 - The above incentive stock options granted to directors, officers and consultants were cancelled.	**N/A**

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.
None

16. Provide details of any changes in directors, officers or committee members.

On February 6, 2023 the Company announced that Roger Johnson had resigned as a director of the GHG.

On February 14, 2023 the Company announced the appointment of Aurelio Useche and Véronique Laberge and as new Directors of the Company.

Aurelio Useche leverages over 20 years of senior management experience including COO, CFO and CEO in several private and publicly traded corporations in manufacturing, mining exploration, consumer goods and entertainment. Mr. Useche is a CPA, CMA and a graduate of the executive MBA program at Queen's University School of Business. Mr. Useche is also a graduate of the Corporate Directors program at the University of Toronto's Rotman School of Business and of the Masters Certificate program in Risk Management program at York University's Schulich School of Business.

Veronique Laberge began her career in an accounting firm in 2005. She participated in various certification mandates for private companies. Mrs. Laberge then chose to pursue her career in a management position in the field of professional services, an experience that allows her to acquire solid expertise in the business world. In 2018, Mrs. Laberge returned to professional practice as a self-employed practitioner. Specializing in certification mandates, general accounting and as a consultant for public and private companies, she wishes to support companies in their financial management. Also, a chartered professional accountant and holder of the title of auditor, she now has more than 15 years of experience in professional practice.

The Company also announced that Jeff Kilpatrick had resigned as Director of the Company.

Committees Appointments:
– Audit Committee; Veronique Laberge (Chairperson), Aurelio Useche and Curt Huber
– Compensation Committee; Veronique Laberge, Aurelio Useche and Paul Perrault

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **March 5, 2023**.

Curt Huber
Name of Director or Senior Officer

"*Curt Huber*"
Signature

President & CEO
Official Capacity

Issuer Details		
Name of Issuer **Global Hemp Group Inc.**	For Month End **February 2023**	Date of Report YY/MM/DD **2023/03/06**
Issuer Address **#106 – 1169 Mt. Seymour Road**		
City/Province/Postal Code **North Vancouver, BC V7H 2Y4**	Issuer Fax No. **N/A**	Issuer Telephone No. **778-726-2900**
Contact Name **Curt Huber**	Contact Position **President & CEO**	Contact Telephone No. **778-726-2900**
Contact Email Address **info@globalhempgroup.com**	Web Site Address **www.globalhempgroup.com**	